# An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors

> **NCT05166070** · EARLY_PHASE1 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 24 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** RD133

## Key facts

- **NCT ID:** NCT05166070
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-01
- **Primary completion:** 2024-01-01
- **Final completion:** 2037-01-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2021-12-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05166070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05166070, "An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05166070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*